Subtype
Prostate Carcinoma
CI-CAN-00006533Explore in graph →
429 active trials16 approved drugs20 evidence items
Loading cancer entity…
Subtype
CI-CAN-00006533Explore in graph →
Clinical trials
1,176 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (184)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00108732 | A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2015 | clinicaltrials |
| NCT01533246 | Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Mar 13, 2015 |
| clinicaltrials |
| NCT00080899 | Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00058214 | Perifosine in Treating Patients With Recurrent Prostate Cancer | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2015 | clinicaltrials |
| NCT00666666 | R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Dec 18, 2014 | clinicaltrials |
| NCT01020305 | Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 5 | Sandy SrinivasOTHER | 1 | Oct 13, 2014 | clinicaltrials |
| NCT02258087 | HDR vs LDR Brachytherapy as Monotherapy in the Treatment of Localized Prostate Cancer.(PROMOBRA) | unknown | Phase 2 / Phase 3 | 50 | National Institute of Oncology, HungaryOTHER | 1 | Oct 7, 2014 | clinicaltrials |
| NCT02054793 | Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC) | withdrawn | Phase 1 / Phase 2 | 0 | Emmanuel Antonarakis, MDOTHER | 1 | Jul 23, 2014 | clinicaltrials |
| NCT00337077 | Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | completed | Phase 2 | 121 | National Cancer Institute (NCI)NIH | 1 | Jun 23, 2014 | clinicaltrials |
| NCT00183924 | Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy. | completed | Phase 2 | 20 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00087139 | Ixabepilone in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 124 | National Cancer Institute (NCI)NIH | 1 | May 9, 2014 | clinicaltrials |
| NCT00684970 | Phase IIB Clinical Trial of Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC)(TLH-202) | unknown | Phase 2 | 100 | Tiltan Pharma Ltd.INDUSTRY | 1 | Dec 5, 2013 | clinicaltrials |
| NCT00181597 | Trilostane for Androgen-Independent Prostate Cancer | completed | Phase 2 | 24 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Dec 3, 2013 | clinicaltrials |
| NCT00003517 | Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00016107 | Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 72 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00039104 | Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00040755 | BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy | completed | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2013 | clinicaltrials |
| NCT00096499 | SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00005039 | Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer) | terminated | Phase 2 | 86 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00109811 | Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT01663415 | A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | Astellas Pharma Global Development, Inc.INDUSTRY | 0 | Sep 17, 2012 | clinicaltrials |
| NCT01487902 | The Role of Androgen Deprivation Treatment (ADT) in Docetaxe-Prednisolone Chemotherapy for Castrate-Resistant Prostatic Cancer | unknown | Phase 2 | 90 | Asan Medical CenterOTHER | 1 | Dec 8, 2011 | clinicaltrials |
| NCT00430235 | A Study of BAY 43-9006 in Combination With Bicalutamide in Patients With Chemo-Naïve Hormone Refractory Prostate Cancer | completed | Phase 2 | 39 | British Columbia Cancer AgencyOTHER | 1 | Aug 5, 2010 | clinicaltrials |
| NCT00181558 | Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone | completed | Phase 2 | 44 | Massachusetts General HospitalOTHER | 1 | May 10, 2010 | clinicaltrials |
| NCT00140478 | Mifepristone (RU-486) in Androgen Independent Prostate Cancer | completed | Phase 2 | 48 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 9, 2009 | clinicaltrials |
Data updated 22 days agoSource updated Jun 30, 2015source: clinicaltrials